Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant 9-valent - Shanghai Zerun Biotechnology

Next Previous
Drug Profile

Human papillomavirus vaccine recombinant 9-valent - Shanghai Zerun Biotechnology

Alternative Names: 9-valent (Types 6, 11, 16, 18,31,33,45,52 and 58) HPV vaccine - Shanghai Zerun Biotechnology; 9-valent HPV Recombinant Vaccine - Shanghai Zerun Biotechnology; 9-valent HPV vaccine - Shanghai Zerun Biotechnology; Human Papillomavirus 9-valent vaccine - Zerun Biotechnology Co

Latest Information Update: 21 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Zerun Biotechnology Co
  • Class Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Human papillomavirus infections

Most Recent Events

  • 01 Sep 2022 Phase-III clinical trials in Human papillomavirus infections (In adolescents, In children, Prevention, In adults) in China (IM) (Shanghai Zerun Biotechnology pipeline, September 2022) (NCT05580341; 312-HPV-2002)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Human-papillomavirus-infections(In adolescents, In children, Prevention, In adults) in China (IM, Injection)
  • 30 Apr 2020 Shanghai Zerun Biotechnology completes a phase I trial in (indication) in Human papillomavirus infections (Prevention; In children; In adolescents; In adults ) in China (IM) (NCT03900572)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top